Publicaciones en colaboración con investigadores/as de University of Bari Aldo Moro (93)

2024

  1. Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?

    Arthritis Care and Research, Vol. 76, Núm. 1, pp. 88-97

  2. Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma

    Clinical Genitourinary Cancer

  3. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice

    Seminars in Arthritis and Rheumatism, Vol. 65

2023

  1. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Nature Medicine, Vol. 29, Núm. 7, pp. 1867-1876

  2. Biomarkers for risk stratification and antibiotic stewardship in elderly patients

    Aging Clinical and Experimental Research, Vol. 35, Núm. 5, pp. 925-935

  3. Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD

    Journal of the American Society of Nephrology : JASN, Vol. 34, Núm. 6, pp. 955-968

  4. Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration

    Arthritis Research and Therapy, Vol. 25, Núm. 1

  5. Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis

    Digital Health, Vol. 9

  6. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

    The Lancet Regional Health - Europe, Vol. 33

  7. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

    The Lancet, Vol. 402, Núm. 10417, pp. 2077-2090

  8. Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD

    Clinical journal of the American Society of Nephrology : CJASN, Vol. 18, Núm. 2, pp. 183-192

  9. Post-COVID-19 Symptoms and Heart Disease: Incidence, Prognostic Factors, Outcomes and Vaccination: Results from a Multi-Center International Prospective Registry (HOPE 2)

    Journal of Clinical Medicine, Vol. 12, Núm. 2

  10. Predictors of treatment switching in the Big Multiple Sclerosis Data Network

    Frontiers in Neurology, Vol. 14

  11. Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network

    Arthritis and Rheumatology

  12. Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis: Results from the EuroSpA Research Collaboration Network

    RMD Open, Vol. 9, Núm. 4

2022

  1. Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression

    Journal of the American Society of Nephrology : JASN, Vol. 33, Núm. 2, pp. 291-303

  2. Cabozantinib combination therapy for the treatment of solid tumors: a systematic review

    Therapeutic Advances in Medical Oncology, Vol. 14

  3. Cabozantinib for the treatment of solid tumors: a systematic review

    Therapeutic Advances in Medical Oncology, Vol. 14

  4. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

    PharmacoEconomics, Vol. 40, Núm. 3, pp. 323-339

  5. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

    Cancer, Vol. 128, Núm. 11, pp. 2085-2097